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1 Carbamazepine, 5Hdibenz[b,f]azepine5car
boxamide, is an antiepileptic drug widely used for
treatment of simple and complex partial seizures,
trigeminal neuralgia, and bipolar affective disorder. It
selectively inhibits the high frequency epileptic foci
without affecting the normal neural activity by block
ing sodium channels [1–3]. The usual adult therapeu
tic levels are between 4 and 12 µg/mL [4]. Serious side
effects, such as coma, seizures, respiratory failure and
cardiac conduction defects, develop more frequently
when the serum level of carbamazepine is higher than
15 µg/mL [5–7]. In one report, approximately 13% of
patients died after massive carbamazepine overdose
[8]. Thus, it is critical to monitor the serum drug level.
Many analytic techniques have been applied to the
determination of the carbamazepine level, such as
high performance liquid chromatography (HPLC),
gas chromatography (GC), gas chromatography com
bined with mass spectrometry and fluorescence polar
ization immunoassay (FPIA) [9–14]. Though the
HPLC technique has the advantages of rapid run times
and excellent resolution, the expense of the equipment
1 The article is published in the original.
and the high maintenance required to keep it running
optimally limit the application in clinical labs. Gas
chromatography has the advantage of very high resolv
ing power provided by the capillary columns that are
typically used. However, the compounds must be not
only sufficiently volatile to be introduced in the gas
phase when the sample is injected into the GC but also
stable so that they do not degrade at the temperatures
required to vaporize them. As a consequence, gas
chromatography is generally limited to nonpolar and
slightly polar molecules, which make up about 20% of
the known organic molecules [15]. In the clinical lab
oratory, immunoassays are more widely used to moni
tor the carbamazepine concentrations in serum or
plasma due to the simplicity of use [16]. Of these
immunoassays, FPIA is accepted in most clinical labs
because it provides accurate and sensitive measure
ment of small toxicology analytes, such as therapeutic
drugs, narcotics, and some hormones, than others.
Electrochemical methods have been proved to be
sensitive and reliable for detection of several electroac
tive drugs such as abacavir and sildenafil citrate. In
comparison with other analytical techniques, electro
chemical techniques are simple, inexpensive, and have
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relatively short analysis time [17–19]. Only a few stud
ies have investigated carbamazepine with electro
chemical techniques such as cyclic voltammetry, dif
ferential pulse polarography and coulometry [20, 21]
and none of them compared the electrochemical tech
nique with the widely used FPIA technique. In this
study, we evaluated the performance of differential
pulse voltammetry (DPV), one of the electrochemical
methods, in carbamazepine analysis and compared it
with the performance of FPIA.
EXPERIMENTAL
Sample preparation. Pure carbamazepine in pow
der form was purchased from MP Biomedicals, Inc.
(Germany). Tetrabutylammonium perchlorate
(TBAP) was obtained from Toyo Kasei Kogyo Co.,
Ltd. (Japan). The tested samples were prepared in
7 different concentrations (0, 2, 4, 8, 12, 20 and
23.6 µg/mL) by dissolving carbamazepine in 0.1 M
TBAP/ acetonitrile. All the other reagents used were
of analytical grade. Doubly distilled water was
obtained by purification through a Millipore water
system.
Voltammetric measurements. Differential pulse
voltammetry (DPV) was performed in a standard
threeelectrode electrochemical cell, in which a BAS
glassy carbon electrode (area = 0.07 cm2) was used as a
working electrode, the glassy carbon electrode was
polished with 0.05 µm alumina on Buehler felt pads
and was ultrasonicated for 2 min to remove the alu
mina residue and a platinum wire was used as the aux
iliary electrode. For analytical application, the follow
ing parameters were employed: DPV pulse amplitude,
50 mV; pulse width: 0.05 (sec); sample width:
0.0167 (sec); pulse period: 0.2 (sec); scan rate:
20 mV/sec. DPV was performed with a CHI421A
(CHI Model 660 series electroanalytical workstation).
All cell potentials were measured by using a home
made Ag/AgCl, KCl (sat.) reference electrode. The
buffer solution contained 0.1 M (C4H9)4NClO4 to sup
port electrolytes in CH3CN. During the voltammetric
measurement a constant flux of N2 was kept over the
solution surface in order to avoid the diffusion of
atmospheric oxygen into the solution of carbam
azepine.
With DPV techniques, the current is measured at
two points for each pulse: just before the application of
the pulse and at the end of the pulse. The difference
between the two measured currents for each pulse is
plotted against the base potential. We used a series of
fixed amplitude potential pulses and increased the
base potential slowly. The carbamazepine has two
reducible sites in protic solvents, the stibene based eth
ylenic bond and the amide’s CO double bond. The
anodic peaks exhibited is attributed to the phenolic
OH group in the carbamazepine structure. One OH
group in each structure is oxidized to imnoquinone
group with the involvement of one electron and one
proton. The typical currentpotential curve of car
bamazepine is shown in Fig. 1. The +1.24 V peak was
adapted in our study for analysis since the peak is
higher than that of –2.2 V. The concentrationrelated
currents are represented in Fig. 2. According to the
calibration curve shown in Fig. 2, the concentration of
the tested samples can be calculated from the current.
FPIA technique. The FPIA technique was per
formed by a qualified technician using an Abbott TDx
analyzer with standard operating procedure. All the
required reagents were purchased from Abbott Labo
ratories (Chicago, IL, USA).
Method validation. Precision. Tested samples of 4, 8,
12 µg/mL of carbamazepine were analyzed 20 times
by the DPV technique and four tests per run for 5 runs
by the FPIA technique to evaluate the betweenrun
variation. Comparison of the within run variation is
not possible since the DPV technique can only test one
sample per run. The results are expressed as coefficient
of variation (CV, %).
Accuracy. Tested samples of 2, 4, 8, 12, 20, and
23.6 µg/mL of carbamazepine were analyzed 5 times
by the DPV technique and FPIA technique, respec
tively. The results are expressed in bias, the difference
between the mean of each concentration and the ref
erence concentration, and in the percent recovery,
which is calculated by dividing the bias by the refer
ence concentration. The positive bias indicates that
the mean concentration is higher than the reference
concentration, whereas the negative bias indicates that
the mean concentration is lower than the reference
concentration.
Linearity. The 7 different concentrations of the
tested samples were tested three times with each tech
nique. The mean of the three results was correlated
with the theoretical concentration of each sample.
The results are expressed as the coefficient of determi
nation (R2, RSQ).
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Fig. 1. Typical DPV potential of carbamazepine occurs at
+1.24 V (A) and ⎯2.2V (B).
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Detection limit. The tested sample with 0 µg/mL was
analyzed 10 times with each technique. The tested
sample of 2 µg/mL was diluted serially and analyzed
10 times with each technique as well. Then the mean
and the CV of the results were calculated. The minimal
concentrations indicating that the mean –3SD was
higher than the mean +3SD of the blank results were
interpreted as the detection limit of each technique.
Statistical analysis. According to the FDA guide
lines for bioanalytical methods [22], it is recom
mended that the accuracy and precision of the assay
should be within 15% of the actual value except at the
lower limit of quantitation (LLOQ), where it should
not deviate by more than 20%.
Using Pearson’s correlation, a linear relationship
was calculated between the results obtained with the
FPIA technique and the reference concentration as
well as between the results obtained with the DPV
technique and the reference concentration. A ttest
was used for the calculation of the statistical signifi
cance of r (Pearson’s Correlation Coefficient). A
P value of less than 0.05 was considered to be statisti
cally significant. The coefficient of determination (R2,
RSQ) was also calculated.
Agreement between the two methods and agree
ment of each method with the reference value concen
tration are presented using the Bland–Altman
approach, by plotting the percent difference between
the two methods versus the mean concentration deter
mined. We considered outliers values to be outside two
standard deviations from the mean.
RESULTS AND DISCUSSION
The results of the precision, accuracy, linearity and
the detection limit of the DPV and the FPIA tech
niques are listed in table. The coefficient of variation
for the DPV technique at the concentrations of 4, 8,
and 12 µg/mL was 3.27, 2.35, and 2.87%, respectively.
The coefficient of variation for the FPIA technique at
the concentrations of 4, 8, and 12 µg/mL was 3.26,
2.65, and 2.44%, respectively. The precision of the
DPV and FPIA techniques was comparable.
The bias for the DPV technique at the concentra
tions of 2, 4, 8, 12, 20, and 23.6 µg/mL was
⎯0.38 µg/mL (–18.89%), –0.30 µg/mL (–7.38%),
0.53 µg/mL (6.62%), 0.59 µg/mL (4.88%),
⎯0.29 µg/mL (–1.44%), and –0.14 µg/mL (–0.61%),
respectively. The bias for the FPIA technique at the
concentrations of 2, 4, 8, 12, 20, and 23.6 µg/mL was
–0.03 µg/mL (–1.4%), –0.13 µg/mL (–3.28%),
0.19 µg/mL (2.32%), –0.52 µg/mL (–4.31%),
1.55 µg/mL (7.76%), and 0.03 µg/mL (0.13%),
respectively. The performance of both techniques was
within the FDA guidelines for bioanalytical methods
[22]. Although the bias in the DPV technique seems
bigger than that in the FPIA technique, it ensures the
clinical applicability of the DPV technique.
In comparison with the reference samples, the
RSQ was 0.993 for the DPV technique and 0.994 for
the FPIA technique. The ttest for the statistical sig
nificance of r (Pearson’s Correlation Coefficient) in
both the DPV and FPIA techniques was P < 0.001.
The detection limit was 1 µg/mL for the DPV tech
nique and 0.5 µg/mL for the FPIA technique.
The Bland–Altman approach for both the DPV
and reference value concentration (Fig. 3) and the
FPIA and reference value concentration (Fig. 4)
showed good agreement.
Electrochemical analysis determines the concen
tration of an analyte by measuring changes in current
in response to an applied voltage with respect to time
using an electrode. According to Faraday’s Law, the
change reflects the amount of analytes that undergo
oxidation or reduction. The most commonly used
electrochemical techniques are constant potential
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Fig. 2. DPV voltammograms of carbamazepine under optimum conditions: (a) 2.0 × 10–4 M; (b) 1.0 × 10–4 M; (c) 4.0 × 10–5 M;
(d) 1.0 × 10–5 M; (e) 1.0 × 10–6 M at +1.24 V (A) and ⎯2.2 V (B).
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amperometry, highspeed chronoamperometry, fast
cyclic voltammetry (FCV) and differential pulse volt
ammetry. Constant potential amperometry monitors
the change of current over time by applying a constant
potential. The time resolution of constant potential
amperometry is very good. However, the chemical
selectivity is limited because all species with oxidation
potentials below the applied voltage will be oxidized
and thus will change the current. Chronoamperome
try is a squarewavepulsed voltammetric technique.
By calculating the ratio of the peak oxidation current
versus the peak reduction current, some limited infor
mation about the identity of the analytes can be
obtained. Fast cyclic voltammetry is a linear sweep
voltammetric technique, which measures the current
response over a range of potentials. Additional infor
mation about the electrolyzed species can be obtained
by using a backgroundsubtracted voltammogram.
Fast cyclic voltammetry is, as its name implies, rela
tively fast (about 100 msec/scan). However, the signal
tonoise ratio decreases as the scan rate increases. Dif
ferential pulse voltammetry is a hybrid form of linear
sweep and pulsed voltammetries. Though the scan
rates are relatively slow (200 sec/scan, about
20 mV/sec), since multiple pulses in the waveform are
required, the selectivity of differential pulse voltam
metry is higher than that of other types of voltammetry.
According to our results, the precision and linearity
of the DPV technique are as good as those of the FPIA
technique. Though the accuracy of the DPV tech
The results for the precision, accuracy, linearity and detection limit of the DPV and FPIA techniques
DPV FPIA
Precision (CV, %)
4 µg/mL 3.27 3.26
8 µg/mL 2.35 2.65
12 µg/mL 2.87 2.44
Accuracy (Bias, µg/mL; %)
2 µg/mL –0.38 (–18.89%) –0.03 (–1.40%)
4 µg/mL –0.30 (–7.38%) –0.13 (–3.28%)
8 µg/mL 0.53 (6.62%) 0.19 (2.32%)
12 µg/mL 0.59 (4.88%) –0.52 (–4.31%)
20 µg/mL –0.29 (–1.44%) 1.55 (7.76%)
23.6 µg/mL –0.14 (–0.61%) 0.03 (0.13%)
Linearity (RSQ) 0.993 0.994
Detection limit (µg/mL) 1 0.5
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Fig. 3. BlandAltman plots of the DPV results and refer
ence value concentrations. The solid line represents the
mean difference, and the dashed line represents 1.96 SD.
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Fig. 4. BlandAltman plots of the FPIA results and refer
ence value concentrations. The solid line represents the
mean difference, and the dashed line represents 1.96 SD.
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nique is not as good as that of the FPIA technique at
the level of 2 ng/mL, it is still within the 20% limit of
the FDA guidelines for the lower limit of quantitation
[22], which allows higher bias than in other concen
trations due to the nature of the higher variation of
analytic techniques and the lower effect on clinical
diagnosis at the lower concentration. Thus, this disad
vantage should have no adverse effect in clinical appli
cation. At the other concentrations that play more
important roles in clinical monitoring, the bias recom
mendation of the FDA guidelines is 15%. The accu
racy of the DPV technique is not only comparable
with that of the FPIA technique, but is also within the
FDA guidelines at the concentrations between
4 µg/mL and 23.6 µg/mL. Similar condition is also
noted for the detection limit. The detection limit of
the DPV technique was higher than that of the FPIA
technique. However, in clinical application, the thera
peutic level of carbamazepine is 4–12 µg/mL.
Whether the detection limit is 0.5 µg/mL (for the
FPIA technique) or 1 µg/mL (for the DPV technique)
makes no apparent difference in clinical application.
In addition to the aforementioned advantages, the
electrochemical methods also advantaged by the
required instrumentation is relatively inexpensive,
simple, and the required reagents are of longer dura
tion for the validity. The methods are capable of deter
mining elements accurately at trace and ultratrace
levels [23] in relatively short analysis time so as to con
tinuously monitor the serum level [24]. Besides, elec
trochemical methods have the potential ability to
determine multielements and drugs at the same time
[25, 26]. Although the possibility of simultaneous
electrochemical determination of structurally similar
isomers may be problematic for DPV in traditional
electrodes, with the advancement of electrodes, such
as the recently developed multiwall carbon nanotubes
modified electrodes, the ability of simultaneous deter
mination of isomers have been proved in dopamine
and serotonin [27], nitrophenol isomers [28], hydro
quinone, catechol and resorcinol [29, 30], and cate
chol and hydroquinone [31]. Almost all substance
contained N, S, O would interfere with DPV result.
Pretreatment of test samples is therefore very impor
tant. With well pretreatment of samples, DPV can
determine the target drugs in high sensitivity. Erk et al.
used DPV in the determination of moxifloxacin in
human plasma, which was pretreated with acetoni
trile to precipitate human plasma proteins. Good
recovery was achieved in different drug concentrations
[32].
Immunoassays depend mainly on antibodyanti
gen reactions. They are widely applied in the clinical
laboratory, and include the radioimmunoassay (RIA),
enzymelinked immunosorbent assay (ELISA), fluo
rescence polarization immunoassays (FPIA) and
cloned enzyme donor immunoassay (CEDIA). How
ever, it is well known that the stability of antibodies
may be affected by many factors, such as temperature,
repeated freezing and thawing, dilution and freshness.
Thus the storage and handling of antibodies requires
special care. In contrast, the reagents that are required
for DPV analysis are relatively stable. In addition, the
crossreaction with substances that have similar
chemical structures may result in erroneous results
[33–35]. Kozer et al. had reported a case who was mis
diagnosed as amphetamine abuse by positive urinary
drug screen with FPIA because he took overdosed
mexiletine, an antiarrhythmic agent, in a suicide
attempt [33]. In other words, the immunoassays in
commercial use may not be able to accurately distin
guish some compounds within a class [34, 36]. There
fore, therapeutic drug monitoring with immunoassay
may require the antibodies with low crossreactivity to
the structurally similar species in cases with simulta
neous prescription of drugs in the same class or in
cases where the functioning metabolites have chemi
cal structures similar to those of the original com
pounds. However, these highquality antibodies with
better specificity may increased the expense of assay
ing.
About 75% of carbamazepine in plasma is bound to
protein [37]. After it is metabolized extensively by the
hepatic mixedfunction oxidase system, the primary
metabolite of carbamazepine is 10,11epoxide, which
is quite stable, pharmacologically active, and found in
the plasma and tissues. 10,11epoxide is then metabo
lized further to 10,11dihydroxide. 10,11dihydroxide
may be eliminated in the urine or it may be conjugated
with glucuronic acid [38]. Routine monitoring of the
10,11epoxide metabolite is recommended during
carbamazepine therapy, as serum carbamazepine lev
els alone may not be adequate to detect toxicity in
some patients. Total serum carbamazepine10,11
epoxide levels above 9 µmol/L are associated with
greater side effects than lower levels [4, 39]. Since the
electrochemical technique with multiwall carbon
nanotubemodified electrodes can determine struc
turesimilar isomers simultaneously, it may have the
potency to measure carbamazepine as well as the
pharmacologically active metabolites by interpreting
different peaks in the DPV. Evaluation of the ability of
DPV to detect the level of carbamazepine10,11
epoxide itself and simultaneously with the carbam
azepine level is now ongoing.
In this study, we used the reference concentration
sample for DPV validation. However, in clinical appli
cation, the tested material, such as serum, contains
many other elements besides the pure chemical mate
rial that we used. Before the DPV technique can be
applied in the clinical monitoring of carbamazepine, it
needs further evaluation. Based on the encouraging
results of this study, we plan to use serum as a test sam
ple in future research.
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***
The performance of the DVP technique for car
bamazepine evaluation is comparable with that of the
FPIA technique and is also within the recommended
FDA guidelines. With the advantages of lower cost,
shorter analysis time, and relatively less sensitivity to
environmental change, such as temperature and acid
ity, the DVP technique has the potential for concur
rent functional metabolite analysis and continuous
monitoring. In conclusion, we consider the DVP tech
nique may be a good alternative for carbamazepine
analysis.
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